Creative Biolabs has accumulated extensive experience in antibody discovery and generation. We have developed a unique high-throughput B cell sorting platform to develop Native™ monoclonal antibodies for a wide range of applications.
The approval of the first murine monoclonal antibody (mAb) drug opened the prologue of therapeutic antibody development. Today, mAbs drugs play an inestimable role in the treatment of tumor and autoimmune diseases due to their targeting, high efficiency, and unique action mechanisms. The dramatic progress made by therapeutic mAb drugs owes to the continuous development and innovation of antibody technologies, among which B cell antibody technology is a rapid and powerful approach for Native™ antibody development and research.
B cell antibody technology, also known as single B cell sorting, is an efficient and high throughput strategy that generates fully human mAbs or natural mAbs of different species directly from host B cells. Antigen-specific B cells are obtained by sorting and isolating them from the peripheral blood or lymphoid tissue. After amplifying and sequencing, the VH and VL genes of the target antibody are cloned into vectors and expressed in cell culture systems. B cell antibody technology can retain the Native™ antibody repertoire and remarkably shorten the lead time of antibody development.
Fig.1 Scheme of the single B cell antibody technology. (Ojima-Kato, et al., 2018)
Single B cell sorting technology-based Native™ antibody discovery displays great potential in a wide range of applications, especially in the therapy development for human disease treatment. Another outstanding application of this technology is the investigation of the human immune system and autoimmune diseases. Single B cell sorting technology allows us to isolate B cells at any stage, which makes it possible to study the function and mechanism of humoral immune and autoimmunity in depth. For example, scientists examined and determined the self-reactivity of B cells in healthy individuals by single B cell sorting technology. They found that the majority of early immature B cells were self-reactive and secreted autoantibodies. Additionally, with the advantages of naturally paired antibody chains and in vivo affinity, single B cell sorting technology is a convenient approach for developing therapeutic mAbs for the treatment of autoimmune diseases.
Based on our specialized B cell sorting platform, Creative Biolabs provides optimized solutions and services to advance Native™ antibody discovery. If you are interested or have any questions, please feel free to contact us.
Reference
